Summary
As the world continues to deal with COVID-19, economies are moving into recession, under multiple adverse factors, the GDP of European and American countries in the second quarter suffered a historical contraction. At an annualized rate, the US GDP fell by 32.9% month on month, while the overall GDP of the euro zone fell by 12.1%.
Moreover, the economic prospects of Europe and the United States in the third quarter under the epidemic situation are hardly optimistic. The resumption of work and production not only brought economic data back, but also triggered a rebound in the epidemic situation. At present, the United States is still the 'epicenter' of the global epidemic. The total number of confirmed cases has exceeded 4.8 million, and the epidemic situation in some European countries has also rebounded. Affected by this, more than 20 states in the United States have announced the suspension or withdrawal of part of the economic restart plan. Britain and Italy have also decided to extend the state of emergency. The rebound of the epidemic situation has posed considerable risks to the economic prospects of Europe and the United States.
In the second quarter of this year, US GDP shrank by 9.5% on a month on month basis, or 32.9% at an annual rate, the largest decline since the 1940s. Data show that the sharp decline in personal consumption is the main drag on the U.S. GDP growth in the second quarter.
Compared with the United States, Europe's economic contraction in the second quarter was smaller, but it was also the lowest on record, with Germany and France contracting more than 10%. According to the data released by the Federal Bureau of statistics, Germany's GDP fell by 10.1% in the second quarter after adjusting for prices, seasons and working days, the largest decline since the quarterly economic data were available in 1970.
Thanks to the effective control and policy support of the new epidemic, China's economy rebounded sharply in the second quarter. The growth rate of manufacturing industry, which accounted for about 28% of GDP, rebounded sharply to 4.4% from the negative value in the first quarter. Chinese original equipment manufacturers (OEMs) and suppliers are ramping up production. And there are increased investments in digital footprints in manufacturing. OEMs in other parts of the world are offering incentives to drive sales. XYZResearch published a report for global Darifenacin HBr market in this environment.
In terms of revenue, this research report indicated that the global Darifenacin HBr market was valued at USD XXX million in 2019, and it is expected to reach a value of USD XXX million by 2026, at a CAGR of XX % over the forecast period 2021-2026. Correspondingly, the forecast analysis of Darifenacin HBr industry comprises of China, USA, Japan, India, Korea and South America, with the production and revenue data in each of the sub-segments.
The ????Megafine Pharma aims at producing XX Darifenacin HBr in 2020, with XX % production to take place in global market, ????Dalian Wista Pharma accounts for a volume share of XX %.
Regional Segmentation (Value; Revenue, USD Million, 2015 - 2026) of Darifenacin HBr Market by XYZResearch Include
China
EU
USA
Japan
India
Southeast Asia
South America
Competitive Analysis; Who are the Major Players in Darifenacin HBr Market?
Megafine Pharma
Dalian Wista Pharma
Emcure Pharmaceuticals
Merix Laboratories
Sino-Strong Pharmaceutical
...
Major Type of Darifenacin HBr Covered in XYZResearch report:
≥99.0%
<99.0%
Application Segments Covered in XYZResearch Market
Overactive Bladder
Application 2
Application 3
For any other requirements, please feel free to contact us and we will provide you customized report.
Table of Contents
Global Darifenacin HBr Market Analysis 2020, With Top Companies, Production, Revenue, Consumption, Price and Growth Rate
1 Market Scope
1.1 Product Details and Introduction
1.1.1 ≥99.0% -Product Introduction and Major Manufacturers
1.1.2 <99.0% -Product Introduction and Major Manufacturers
1.2 Market Snapshot
1.2.1 Major Companies Overview
1.2.2 Market Concentration
1.2.3 Six-Year Compound Annual Growth Rate (CAGR)
2 Global Darifenacin HBr Market Assessment, by Segmentation
2.1 Type Breakdown Estimates & Forecast, Sales Volume (2015-2026)
2.2 Type Breakdown Estimates & Forecast, Sales Value (2015-2026)
2.3 Application Breakdown Estimates & Forecast, by Application (2015-2026)
3 Regional Market Analysis
3.1 China Darifenacin HBr Market
3.1.1 Top Companies leading Darifenacin HBr Development in China (2015-2020)
3.1.2 Sales Value of Major Company in China Market (2015-2020)
3.1.3 China Darifenacin HBr Price (USD/Unit), by Type (2019-2020)
3.1.4 Sales in China Market, by Type (2015-2026)
3.2 EU Darifenacin HBr Market
3.2.1 Top Companies leading Darifenacin HBr Development in EU (2015-2020)
3.2.2 Sales Value of Major Company in EU Market (2015-2020)
3.2.3 EU Darifenacin HBr Price (USD/Unit), by Type (2019-2020)
3.2.4 Sales in EU Market, by Type (2015-2026)
3.3 USA Darifenacin HBr Market
3.3.1 Top Companies leading Darifenacin HBr Development in USA (2015-2020)
3.3.2 Sales Value of Major Company in USA Market (2015-2020)
3.3.3 USA Darifenacin HBr Price (USD/Unit), by Type (2019-2020)
3.3.4 Sales in USA Market, by Type (2015-2026)
3.4 Japan Darifenacin HBr Market
3.4.1 Top Companies leading Darifenacin HBr Development in Japan (2015-2020)
3.4.2 Sales Value of Major Company in Japan Market (2015-2020)
3.4.3 Japan Darifenacin HBr Price (USD/Unit), by Type (2019-2020)
3.4.4 Sales in Japan Market, by Type (2015-2026)
3.5 India Darifenacin HBr Market
3.5.1 Top Companies leading Darifenacin HBr Development in India (2015-2020)
3.5.2 Sales Value of Major Company in India Market (2015-2020)
3.5.3 India Darifenacin HBr Price (USD/Unit), by Type (2019-2020)
3.5.4 Sales in India Market, by Type (2015-2026)
3.6 Southeast Asia Darifenacin HBr Market
3.6.1 Top Companies leading Darifenacin HBr Development in Southeast Asia (2015-2020)
3.6.2 Sales Value of Major Company in Southeast Asia Market (2015-2020)
3.6.3 Southeast Asia Darifenacin HBr Price (USD/Unit), by Type (2019-2020)
3.6.4 Sales in Southeast Asia Market, by Type (2015-2026)
3.7 South America Darifenacin HBr Market
3.7.1 Top Companies leading Darifenacin HBr Development in South America (2015-2020)
3.7.2 Sales Value of Major Company in South America Market (2015-2020)
3.7.3 South America Darifenacin HBr Price (USD/Unit), by Type (2019-2020)
3.7.4 Sales in South America Market, by Type (2015-2026)
4 Value Chain (Impact of COVID-19)
4.1 Darifenacin HBr Value Chain Analysis
4.1.1 Upstream
4.1.2 Downstream
4.2 COVID-19 Impact on Darifenacin HBr Industry
4.2.1 Industrial Policy Issued Under the Epidemic Situation
4.3 Cost-Under the Epidemic Situation
4.3.1 Cost of Raw Material
4.4 Channel Analysis
4.4.1 Distribution Channel-Under the Epidemic Situation
4.4.2 Distributors
5 Regional Market Forecast (2021-2026)
5.1 Global Darifenacin HBr Sales and Growth Rate (2021-2026)
5.2 Global Darifenacin HBr Sales Value and Growth Rate (2021-2026)
6 Darifenacin HBr Competitive Analysis
6.1 Megafine Pharma
6.1.1 Megafine Pharma Company Profiles
6.1.2 Megafine Pharma Product Introduction
6.1.3 Megafine Pharma Darifenacin HBr Production, Revenue (2015-2020)
6.1.4 SWOT Analysis
6.2 Dalian Wista Pharma
6.2.1 Dalian Wista Pharma Company Profiles
6.2.2 Dalian Wista Pharma Product Introduction
6.2.3 Dalian Wista Pharma Darifenacin HBr Production, Revenue (2015-2020)
6.2.4 SWOT Analysis
6.3 Emcure Pharmaceuticals
6.3.1 Emcure Pharmaceuticals Company Profiles
6.3.2 Emcure Pharmaceuticals Product Introduction
6.3.3 Emcure Pharmaceuticals Darifenacin HBr Production, Revenue (2015-2020)
6.3.4 SWOT Analysis
6.4 Merix Laboratories
6.4.1 Merix Laboratories Company Profiles
6.4.2 Merix Laboratories Product Introduction
6.4.3 Merix Laboratories Darifenacin HBr Production, Revenue (2015-2020)
6.4.4 SWOT Analysis
6.5 Sino-Strong Pharmaceutical
6.5.1 Sino-Strong Pharmaceutical Company Profiles
6.5.2 Sino-Strong Pharmaceutical Product Introduction
6.5.3 Sino-Strong Pharmaceutical Darifenacin HBr Production, Revenue (2015-2020)
6.5.4 SWOT Analysis
7 Conclusion
The global Darifenacin HBr market is expected to reach US$ XX Million by 2028, with a CAGR of XX% from 2023 to 2028, based on HNY Research newly published report.
The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market players in this fiel...
The research team projects that the Darifenacin HBr market size will grow from XXX in 2020 to XXX by 2027, at an estimated CAGR of XX. The base year considered for the study is 2020, and the market size is projected from 2020 to 2027.
The prime objective of this report is to help the user u...
Summary
As the world continues to deal with COVID-19, economies are moving into recession, under multiple adverse factors, the GDP of European and American countries in the second quarter suffered a historical contraction. At an annualized rate, the US GDP fell by 32.9% month on month, ...
The 'Global and Chinese Darifenacin Industry, 2012-2022 Market Research Report' is a professional and in-depth study on the current state of the global Darifenacin industry with a focus on the Chinese market. The report provides key statistics on the market status of the Darifenacin manufacturers an...